Abstract： AIM: To observe the clinical significance and changes of cytoimmunity,humoral immunity and immune regulatory factors after the administration of rhGH on patients with obstructive jaundice (OJ).METHODS: A prospective,randomized and controlled clinical study was performed,and 36 OJ cases were randomly divided into control group (A group,n = 18) and rhGH group (B group,n =18). rhGH were added in group B. A dynamic investigation of cytoimmunity indices (CD3+,CD4+and CD4+/CD8+),humoral immunity indices (IgA,IgG and IgM) and serum immune regulatory factors (IL-2,IL-6 and TNF-α) were conducted and mortality rate and complication rate of patients of two groups before therapy and at 1,8 d after operation were evaluated.RESULTS: Indexes of cytoimmunity indices (CD3+,CD4+ and CD4+/CD8+) in B group were obviously improved than A (42.32% ± 4.19%vs 31.51% ± 4.42%;26.36% ± 4.25% vs 19.29% ±4.27%;1.22 ± 0.20 vs 0.95 ± 0.12,all P < 0.05). Humoral immunity indices (IgA,IgG and IgM) in B group were obviously improved than group A 8 days after treatment (2.42 ± 0.11 g/L vs 1.41 ±013 g/L;6.88 ± 0.18 g/L vs 4.89 ± 0.15 g/L;1.84± 0.18 g/L vs 1.28 ± 0.24 g/L,all P < 0.05). Erum immune regulatory factors (IL-6 and TNF-α)were significantly decreased in B group (0.42± 0.11 mg/L vs 0.86 ± 0.10 mg/L;11.04 ± 1.52pmol/L vs 18.24 ± 1.22 pmol/L,both P < 0.05),IL-2 was obviously improved in group B (1.92± 0.15 mg/L vs 1.14 ± 0.12 mg/L,P < 0.05),and mortality rate and complication rate in group B were obviously lower than group A (22.22% vs 44.44%,0.00% vs 5.56%,both P < 0.05). CONCLUSION: RhGH has a direct immunoregulatory effect on patients with obstructive jaudice,which improves immunity of patients with obstructive jaundice and is good for their recovery.